Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Diest – page 103

1 961 clinical trials in Diest, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Diest at a glance
1 961
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 961 trials in Diest

Open in trial search

Study on the Safety and Effectiveness of Opelconazole with Other Antifungal Treatments for Patients with Hard-to-Treat Lung Aspergillosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Opelconazole
  • Sponsor:Pulmocide Limited

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Kite Pharma Inc.

Study of Irinotecan with S1 or 5-Fluorouracil for Patients with Metastatic Pancreatic Cancer After Gemcitabine Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Amsterdam UMC Stichting

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Safety Study of Tradipitant for Patients with Idiopathic or Diabetic Gastroparesis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tradipitant
  • Sponsor:Vanda Pharmaceuticals Inc.

Study comparing carboplatin-cyclophosphamide versus paclitaxel with atezolizumab as first treatment for advanced triple negative breast cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BOOG Study Center B.V.

Multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of tolDC for Patients with Relapsing Remitting and Progressive Multiple Sclerosis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Toldc
  • Sponsor:Antwerp University Hospital

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing Dabigatran with Ticagrelor or Clopidogrel for Patients with Acute Coronary Syndrome Undergoing PCI

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ticagrelor
  • Sponsor:Stichting Zuyderland Medisch Centrum

Cardiac amyloidosis

Not recruiting

Study of Patisiran for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Patisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.